AU2010338669A1 - Beta-carbolines for use in the treatment of hearing loss and vertigo - Google Patents

Beta-carbolines for use in the treatment of hearing loss and vertigo Download PDF

Info

Publication number
AU2010338669A1
AU2010338669A1 AU2010338669A AU2010338669A AU2010338669A1 AU 2010338669 A1 AU2010338669 A1 AU 2010338669A1 AU 2010338669 A AU2010338669 A AU 2010338669A AU 2010338669 A AU2010338669 A AU 2010338669A AU 2010338669 A1 AU2010338669 A1 AU 2010338669A1
Authority
AU
Australia
Prior art keywords
carboline
cyclo
cec
cech
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010338669A
Other languages
English (en)
Inventor
Hans Rommelspacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUDIOCURE PHARMA GmbH
Original Assignee
AUDIOCURE PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AUDIOCURE PHARMA GmbH filed Critical AUDIOCURE PHARMA GmbH
Publication of AU2010338669A1 publication Critical patent/AU2010338669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010338669A 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo Abandoned AU2010338669A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102009060811.7 2009-12-28
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
US61/282,395 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
AU2010338669A1 true AU2010338669A1 (en) 2012-06-21

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010338669A Abandoned AU2010338669A1 (en) 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo

Country Status (17)

Country Link
US (1) US9107914B2 (cg-RX-API-DMAC7.html)
EP (1) EP2519238B1 (cg-RX-API-DMAC7.html)
JP (1) JP5627705B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120098855A (cg-RX-API-DMAC7.html)
CN (1) CN102844029A (cg-RX-API-DMAC7.html)
AU (1) AU2010338669A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012015967B1 (cg-RX-API-DMAC7.html)
CA (1) CA2785233C (cg-RX-API-DMAC7.html)
DE (1) DE112010005017A5 (cg-RX-API-DMAC7.html)
IL (1) IL220661A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN05066A (cg-RX-API-DMAC7.html)
MX (1) MX2012007678A (cg-RX-API-DMAC7.html)
NZ (1) NZ600478A (cg-RX-API-DMAC7.html)
RU (1) RU2012132429A (cg-RX-API-DMAC7.html)
SG (1) SG181599A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011079841A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204476B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
SI2968284T1 (sl) 2013-03-14 2021-08-31 Osteoqc Inc. Alkil-amin harmin derivati za pospeševanje rasti kosti
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP7695496B2 (ja) 2018-08-14 2025-06-19 オシフィ セラピューティクス リミティド ライアビリティ カンパニー フルオロβ－カルボリン化合物
EP3836923B1 (en) 2018-08-14 2024-10-16 OssiFi Therapeutics LLC Pyrrolo - dipyridine compounds for the treatment of bone loss
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3849530A4 (en) 2018-09-12 2022-06-22 Hough Ear Institute METHODS OF TREATMENT OF HEARING LOSS AFTER COCHLEAR IMPLANT SURGERY
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
EP1086101B1 (en) * 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
KR20120098855A (ko) 2012-09-05
JP5627705B2 (ja) 2014-11-19
IL220661A (en) 2016-03-31
WO2011079841A1 (de) 2011-07-07
IN2012DN05066A (cg-RX-API-DMAC7.html) 2015-10-09
IL220661A0 (en) 2012-08-30
RU2012132429A (ru) 2014-02-10
JP2013515752A (ja) 2013-05-09
EP2519238A1 (de) 2012-11-07
DE112010005017A5 (de) 2012-10-04
BR112012015967A2 (pt) 2016-04-19
CN102844029A (zh) 2012-12-26
SG181599A1 (en) 2012-07-30
BR112012015967B1 (pt) 2019-08-27
US9107914B2 (en) 2015-08-18
MX2012007678A (es) 2012-09-12
NZ600478A (en) 2013-10-25
CA2785233C (en) 2018-10-09
US20130028958A1 (en) 2013-01-31
ZA201204476B (en) 2014-01-29
CA2785233A1 (en) 2011-06-07
EP2519238B1 (de) 2014-08-13

Similar Documents

Publication Publication Date Title
US9107914B2 (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
ES2248950T3 (es) Utilizacion de cuatro derivados de k-252a.
EP0839040B1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
JP6832358B2 (ja) ５−アミノレブリン酸及び誘導体の塩
US6974823B2 (en) Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
CN117088837A (zh) 乙烯基吡喃酮类化合物及其在治疗阿尔茨海默病中的应用
JP2026500459A (ja) Ｎ－ｎ－ジメチルトリプタミン（ｄｍｔ）およびｄｍｔ類似体組成物、その作製方法、ならびに使用方法
AU2014326708B2 (en) Fluor-9-methyl-beta-carbolines
US6916845B2 (en) Method for prevention and treatment of male and female sexual dysfunction
JP5204943B2 (ja) 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用
WO2021138847A1 (en) Macrolide compound and its use of treatment chronic respiratory disease
HK1222844B (en) FLUOR-9-METHY-β-CARBOLINES
HK1164884A (en) Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient
HK1005363B (en) Use of cgmp - phosphodiesterase inhibitors to treat impotence
JPWO1997025986A1 (ja) 血管内膜肥厚抑制剤
ZA200507367B (en) Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period